221 related articles for article (PubMed ID: 22551397)
1. Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course.
Ueno D; Yao M; Tateishi U; Minamimoto R; Makiyama K; Hayashi N; Sano F; Murakami T; Kishida T; Miura T; Kobayashi K; Noguchi S; Ikeda I; Ohgo Y; Inoue T; Kubota Y; Nakaigawa N
BMC Cancer; 2012 May; 12():162. PubMed ID: 22551397
[TBL] [Abstract][Full Text] [Related]
2. The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ.
Kakizoe M; Yao M; Tateishi U; Minamimoto R; Ueno D; Namura K; Makiyama K; Hayashi N; Sano F; Kishida T; Kobayashi K; Noguchi S; Ikeda I; Ohgo Y; Taguri M; Morita S; Inoue T; Kubota Y; Nakaigawa N
BMC Cancer; 2014 Jun; 14():390. PubMed ID: 24885730
[TBL] [Abstract][Full Text] [Related]
3. One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival.
Ito H; Kondo K; Kawahara T; Kaneta T; Tateishi U; Ueno D; Namura K; Kobayashi K; Miyoshi Y; Yumura Y; Makiyama K; Hayashi N; Hasumi H; Osaka K; Yokomizo Y; Teranishi JI; Hattori Y; Inoue T; Uemura H; Yao M; Nakaigawa N
Cancer Chemother Pharmacol; 2017 May; 79(5):855-861. PubMed ID: 28331985
[TBL] [Abstract][Full Text] [Related]
4. Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
Muriel C; Esteban E; Corral N; Fonseca PJ; Luque M; Berros JP; Fernández Y; Blay P; Fra J; Villanueva N; Sanmamed M; Pardo P; Izquierdo M; Vieitez JM; Estrada E; Lacave ÁJ
Clin Transl Oncol; 2010 Aug; 12(8):562-7. PubMed ID: 20709657
[TBL] [Abstract][Full Text] [Related]
5. Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report.
Namura K; Minamimoto R; Yao M; Makiyama K; Murakami T; Sano F; Hayashi N; Tateishi U; Ishigaki H; Kishida T; Miura T; Kobayashi K; Noguchi S; Inoue T; Kubota Y; Nakaigawa N
BMC Cancer; 2010 Dec; 10():667. PubMed ID: 21129184
[TBL] [Abstract][Full Text] [Related]
6. Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer.
Kayani I; Avril N; Bomanji J; Chowdhury S; Rockall A; Sahdev A; Nathan P; Wilson P; Shamash J; Sharpe K; Lim L; Dickson J; Ell P; Reynolds A; Powles T
Clin Cancer Res; 2011 Sep; 17(18):6021-8. PubMed ID: 21742806
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography.
Lyrdal D; Boijsen M; Suurküla M; Lundstam S; Stierner U
Nucl Med Commun; 2009 Jul; 30(7):519-24. PubMed ID: 19522059
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib.
Lee JH; Park JY; Kim DY; Ahn SH; Han KH; Seo HJ; Lee JD; Choi HJ
Liver Int; 2011 Sep; 31(8):1144-9. PubMed ID: 21745288
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of Quantitative Metabolic Metrics on Baseline Pre-Sunitinib FDG PET/CT in Advanced Renal Cell Carcinoma.
Minamimoto R; Barkhodari A; Harshman L; Srinivas S; Quon A
PLoS One; 2016; 11(4):e0153321. PubMed ID: 27123976
[TBL] [Abstract][Full Text] [Related]
11. Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma.
Revheim ME; Winge-Main AK; Hagen G; Fjeld JG; Fosså SD; Lilleby W
Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):339-43. PubMed ID: 21134733
[TBL] [Abstract][Full Text] [Related]
12. Early assessment with
Tabei T; Nakaigawa N; Kaneta T; Ikeda I; Kondo K; Makiyama K; Hasumi H; Hayashi N; Kawahara T; Izumi K; Osaka K; Muraoka K; Teranishi JI; Miyoshi Y; Yumura Y; Uemura H; Kobayashi K; Inoue T; Yao M
BMC Cancer; 2019 Apr; 19(1):298. PubMed ID: 30940117
[TBL] [Abstract][Full Text] [Related]
13. Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma.
Herrmann E; Marschner N; Grimm MO; Ohlmann CH; Hutzschenreuter U; Overkamp F; Groschek M; Blumenstengel K; Pühse G; Steiner T
World J Urol; 2011 Jun; 29(3):361-6. PubMed ID: 21461939
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
Zimmermann K; Schmittel A; Steiner U; Asemissen AM; Knoedler M; Thiel E; Miller K; Keilholz U
Oncology; 2009; 76(5):350-4. PubMed ID: 19321976
[TBL] [Abstract][Full Text] [Related]
15. The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy.
Nakaigawa N; Kondo K; Ueno D; Namura K; Makiyama K; Kobayashi K; Shioi K; Ikeda I; Kishida T; Kaneta T; Minamimoto R; Tateishi U; Inoue T; Yao M
BMC Cancer; 2017 Jan; 17(1):39. PubMed ID: 28068944
[TBL] [Abstract][Full Text] [Related]
16. FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma.
Nakaigawa N; Kondo K; Kaneta T; Tateishi U; Minamimoto R; Namura K; Ueno D; Kobayashi K; Kishida T; Ikeda I; Hasumi H; Makiyama K; Hayashi N; Osaka K; Muraoka K; Izumi K; Kawahara T; Teranishi JI; Miyoshi Y; Yumura Y; Uemura H; Inoue T; Yao M
Cancer Chemother Pharmacol; 2018 Apr; 81(4):739-744. PubMed ID: 29464355
[TBL] [Abstract][Full Text] [Related]
17. Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib.
Di Fiore F; Rigal O; Ménager C; Michel P; Pfister C
Br J Cancer; 2011 Dec; 105(12):1811-3. PubMed ID: 22095228
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
19. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases.
Porta C; Procopio G; Cartenì G; Sabbatini R; Bearz A; Chiappino I; Ruggeri EM; Re GL; Ricotta R; Zustovich F; Landi L; Calcagno A; Imarisio I; Verzoni E; Rizzo M; Paglino C; Guadalupi V; Bajetta E
BJU Int; 2011 Oct; 108(8 Pt 2):E250-7. PubMed ID: 21599821
[TBL] [Abstract][Full Text] [Related]
20. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
